hydrochlorothiazide has been researched along with Magnesium Deficiency in 10 studies
Hydrochlorothiazide: A thiazide diuretic often considered the prototypical member of this class. It reduces the reabsorption of electrolytes from the renal tubules. This results in increased excretion of water and electrolytes, including sodium, potassium, chloride, and magnesium. It is used in the treatment of several disorders including edema, hypertension, diabetes insipidus, and hypoparathyroidism.
hydrochlorothiazide : A benzothiadiazine that is 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide substituted by a chloro group at position 6 and a sulfonamide at 7. It is diuretic used for the treatment of hypertension and congestive heart failure.
Magnesium Deficiency: A nutritional condition produced by a deficiency of magnesium in the diet, characterized by anorexia, nausea, vomiting, lethargy, and weakness. Symptoms are paresthesias, muscle cramps, irritability, decreased attention span, and mental confusion, possibly requiring months to appear. Deficiency of body magnesium can exist even when serum values are normal. In addition, magnesium deficiency may be organ-selective, since certain tissues become deficient before others. (Harrison's Principles of Internal Medicine, 12th ed, p1936)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The study was performed to ascertain the value of potassium magnesium citrate, magnesium citrate, and potassium citrate in overcoming thiazide-induced hypokalemia and magnesium loss." | 9.09 | Effect of potassium magnesium citrate on thiazide-induced hypokalemia and magnesium loss. ( Pak, CY; Ruml, LA, 1999) |
| "Supplementation of potassium alone and in combination with magnesium was compared in 10 patients with chronic compensated heart failure receiving hydrochlorothiazide 50 mg twice daily for the whole trial." | 9.06 | Comparison of potassium alone and potassium-magnesium supplementation in patients with heart failure using hydrochlorothiazide. ( Gordin, A; Kohvakka, A; Luurila, O; Sundberg, S, 1989) |
| "In a group of elderly patients with systolic hypertension the hypotensive efficacy and adverse effects were studied of hydrochlorothiazide given in daily doses of 25 mg in a year." | 7.67 | [Hypotensive and metabolic effects of small doses of hydrochlorothiazide in the long-term treatment of elderly patients with systolic arterial hypertension]. ( Halawa, B, 1989) |
| "The study was performed to ascertain the value of potassium magnesium citrate, magnesium citrate, and potassium citrate in overcoming thiazide-induced hypokalemia and magnesium loss." | 5.09 | Effect of potassium magnesium citrate on thiazide-induced hypokalemia and magnesium loss. ( Pak, CY; Ruml, LA, 1999) |
| "Supplementation of potassium alone and in combination with magnesium was compared in 10 patients with chronic compensated heart failure receiving hydrochlorothiazide 50 mg twice daily for the whole trial." | 5.06 | Comparison of potassium alone and potassium-magnesium supplementation in patients with heart failure using hydrochlorothiazide. ( Gordin, A; Kohvakka, A; Luurila, O; Sundberg, S, 1989) |
| "In a group of elderly patients with systolic hypertension the hypotensive efficacy and adverse effects were studied of hydrochlorothiazide given in daily doses of 25 mg in a year." | 3.67 | [Hypotensive and metabolic effects of small doses of hydrochlorothiazide in the long-term treatment of elderly patients with systolic arterial hypertension]. ( Halawa, B, 1989) |
| "A group of 8 patients with essential hypertension and 12 patients with recurrent renal calcium stones were treated with 50 mg hydrochlorothiazide daily for a period of 3-10 years." | 3.67 | The myth of long-term thiazide-induced magnesium deficiency. ( Cohen, L; Kitzes, R; Shnaider, H, 1985) |
| "Significant progress of nephrolithiasis and nephrocalcinosis was observed in 80% of patients with permanent hypomagnesemia and in 4% of patients with normalization of serum magnesium level." | 1.27 | Prognosis of urolithiasis and nephrocalcinosis in hypomagnesemia. ( Karlíková, L; Revúsová, V; Suchánek, B; Zvara, V, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (60.00) | 18.7374 |
| 1990's | 3 (30.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (10.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jiang, L | 1 |
| Peng, X | 1 |
| Ma, J | 1 |
| Yuan, T | 1 |
| Qin, Y | 1 |
| Wang, O | 1 |
| Wang, H | 1 |
| Wang, Y | 1 |
| Chen, G | 1 |
| Yue, C | 1 |
| Li, C | 1 |
| Nie, M | 1 |
| Xing, X | 1 |
| Li, X | 1 |
| Lee, X | 1 |
| Chen, L | 1 |
| Ruml, LA | 1 |
| Pak, CY | 1 |
| Seelig, CB | 1 |
| Rolla, G | 1 |
| Bucca, C | 1 |
| Bugiani, M | 1 |
| Oliva, A | 1 |
| Branciforte, L | 1 |
| Halawa, B | 1 |
| Kohvakka, A | 1 |
| Luurila, O | 1 |
| Gordin, A | 1 |
| Sundberg, S | 1 |
| Alexander, BS | 1 |
| Revúsová, V | 1 |
| Zvara, V | 1 |
| Karlíková, L | 1 |
| Suchánek, B | 1 |
| Kuller, L | 1 |
| Farrier, N | 1 |
| Caggiula, A | 1 |
| Borhani, N | 1 |
| Dunkle, S | 1 |
| Cohen, L | 1 |
| Kitzes, R | 1 |
| Shnaider, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Preventing Metabolic Side Effects of Thiazide Diuretics With KMgCitrate[NCT02665117] | 61 participants (Actual) | Interventional | 2015-01-31 | Completed | |||
| A Multi-Site Placebo-Controlled Randomized Double-Blind Study to Evaluate the Efficacy and Safety of Using MPC-5971 as Adjuvant Therapy in Subjects Undergoing Shock Wave Lithotripsy[NCT00860093] | Phase 2 | 135 participants (Actual) | Interventional | 2010-04-30 | Terminated (stopped due to Sponsor Corporate Business Decision) | ||
| [NCT00000487] | Phase 3 | 0 participants | Interventional | 1972-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Will be measured using hepatic magnetic resonance imaging at baseline and at week 16 (NCT02665117)
Timeframe: baseline to week 16
| Intervention | percent (Mean) |
|---|---|
| KMgCit + Chlorthalidone | 0.31 |
| KCl + Chlorthalidone | 1.59 |
Fasting plasma glucose was measured from venous blood sample at week 4 and week 16 (NCT02665117)
Timeframe: week 4 and week 16
| Intervention | mg/dL (Mean) |
|---|---|
| KMgCit + Chlorthalidone | -5.6 |
| KCl + Chlorthalidone | 2.3 |
Will be measured from venous blood sample from week 4 to week 16 (NCT02665117)
Timeframe: week 4 to week 16
| Intervention | pg/ml (Mean) |
|---|---|
| KMgCit + Chlorthalidone | 38.1 |
| KCl + Chlorthalidone | 13.6 |
Will be measured using magnetic resonance imaging at baseline and at week 16 (NCT02665117)
Timeframe: baseline to week 16
| Intervention | mM (Mean) |
|---|---|
| KMgCit + Chlorthalidone | -0.01 |
| KCl + Chlorthalidone | 0.02 |
2 trials available for hydrochlorothiazide and Magnesium Deficiency
| Article | Year |
|---|---|
Effect of potassium magnesium citrate on thiazide-induced hypokalemia and magnesium loss.
Topics: Adult; Citrates; Citric Acid; Diuretics; Drug Combinations; Female; Humans; Hydrochlorothiazide; Hyp | 1999 |
Effect of potassium magnesium citrate on thiazide-induced hypokalemia and magnesium loss.
Topics: Adult; Citrates; Citric Acid; Diuretics; Drug Combinations; Female; Humans; Hydrochlorothiazide; Hyp | 1999 |
Effect of potassium magnesium citrate on thiazide-induced hypokalemia and magnesium loss.
Topics: Adult; Citrates; Citric Acid; Diuretics; Drug Combinations; Female; Humans; Hydrochlorothiazide; Hyp | 1999 |
Effect of potassium magnesium citrate on thiazide-induced hypokalemia and magnesium loss.
Topics: Adult; Citrates; Citric Acid; Diuretics; Drug Combinations; Female; Humans; Hydrochlorothiazide; Hyp | 1999 |
Comparison of potassium alone and potassium-magnesium supplementation in patients with heart failure using hydrochlorothiazide.
Topics: Aged; Blood Pressure; Body Weight; Double-Blind Method; Female; Heart Failure; Heart Rate; Humans; H | 1989 |
8 other studies available for hydrochlorothiazide and Magnesium Deficiency
| Article | Year |
|---|---|
NORMOMAGNESEMIC GITELMAN SYNDROME PATIENTS EXHIBIT A STRONGER REACTION TO THIAZIDE THAN HYPOMAGNESEMIC PATIENTS.
Topics: Adolescent; Adult; Aged; Child; Chlorides; Female; Genotype; Gitelman Syndrome; Humans; Hydrochlorot | 2015 |
Magnesium deficiency in two hypertensive patient groups.
Topics: Antihypertensive Agents; Cardiac Complexes, Premature; Drug Evaluation; Female; Humans; Hydrochlorot | 1990 |
Hypomagnesemia in chronic obstructive lung disease: effect of therapy.
Topics: Administration, Inhalation; Administration, Oral; Adrenal Cortex Hormones; Adrenergic beta-Agonists; | 1990 |
[Hypotensive and metabolic effects of small doses of hydrochlorothiazide in the long-term treatment of elderly patients with systolic arterial hypertension].
Topics: Age Factors; Aged; Humans; Hydrochlorothiazide; Hypertension; Magnesium Deficiency; Male; Potassium | 1989 |
Diuretic-induced CNS magnesium alteration and digoxin intoxication.
Topics: Animals; Arrhythmias, Cardiac; Bendroflumethiazide; Brain Chemistry; Digoxin; Diuretics; Electrocard | 1988 |
Prognosis of urolithiasis and nephrocalcinosis in hypomagnesemia.
Topics: Adolescent; Adult; Aged; Allopurinol; Cation Exchange Resins; Cellulose; Child; Child, Preschool; Ci | 1985 |
Relationship of diuretic therapy and serum magnesium levels among participants in the Multiple Risk Factor Intervention Trial.
Topics: Adult; Blood Pressure; California; Chlorthalidone; Coronary Disease; Diet; Epidemiologic Methods; Hu | 1985 |
The myth of long-term thiazide-induced magnesium deficiency.
Topics: Bone and Bones; Erythrocytes; Humans; Hydrochlorothiazide; Hypertension; Kidney Calculi; Lymphocytes | 1985 |